AVI BioPharma, Inc. (AVII) Reports Solid Q4 Results; Guides FY12
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq hits near three-month low as Amazon, Intel rattle AI trade
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts AVII Hot Sheet
Price: $0.66 --0%
Financial Fact:
Research and development: 34.35M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Financial Fact:
Research and development: 34.35M
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Join SI Premium – FREE
AVI BioPharma, Inc. (NASDAQ: AVII) reported Q4 EPS of ($0.01), $0.05 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $13.6 million versus the consensus estimate of $11.03 million.
Sees FY2012 revenue of $40-$50 million, versus the consensus of $54.14 million. Sees a loss from operations of $30-$35 million.
For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.
Sees FY2012 revenue of $40-$50 million, versus the consensus of $54.14 million. Sees a loss from operations of $30-$35 million.
For earnings history and earnings-related data on AVI BioPharma, Inc. (AVII) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel on FedEx Freight (FDXF): 'Enters Its Post-Breakup Era - Time to Hit the Gym and Focus on Itself'
- Regal-Beloit (RBC) Tops Q3 EPS by 21c ; Offers Guidance
- AbbVie (ABBV) Tops Q3 EPS by 8c, Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
